Affordable Access

Publisher Website

Kynurenines and other novel therapeutic strategies in the treatment of dementia

Therapeutic Advances in Neurological Disorders
SAGE Publications
Publication Date
DOI: 10.1177/1756285613494989
  • Biology
  • Medicine
  • Psychology


Microsoft Word - Kynurenines and other novel therapeutic strategies in the treatment of dementia-revised2.docx 1 Kynurenines and other novel therapeutic strategies in the treatment of dementia Zsófia Majláth1, János Tajti1, László Vécsei* 1, 2 1 University of Szeged, Department of Neurology, Semmelweis u. 6, H-6725, Szeged Hungary 2 Neurology Research Group of the Hungarian Academy of Sciences and University of Szeged, Semmelweis u. 6, H-6725 Szeged, Hungary *Corresponding author. E-mail: [email protected], Tel.: +36-62-545348, Fax: +36-62- 545597 2 Abstract: Dementia is a common neuropsychological disorder with an increasing incidence. The most prevalent of the different types of dementia is Alzheimer’s disease. The underlying pathophysiological features of the cognitive decline are neurodegenerative processes, a cerebrovascular dysfunction and immunological alterations. The therapeutic approaches are still limited, although intensive research is being conducted with the aim of finding neuroprotective strategies. The widely accepted cholinesterase inhibitors and glutamate antagonists did not meet the expectations that they would prevent disease progression, and the research is therefore currently focusing on novel targets. Nonsteroidal anti-inflammatory drugs, secretase inhibitors and statins are promising drug candidates for the prevention and management of different forms of dementia. The kynurenine pathway has been associated with various neurodegenerative disorders and cerebrovascular diseases, it is closely related to neuroinflammatory processes too, and it has been implicated in the pathomechanisms of certain kinds of dementia. Targeting the kynurenine system may be of therapeutic value in the future. Keywords: dementia, Alzheimer’s disease, kynurenine, neuroprotective agents 1. Introduction Dementia is an acquired cognitive decline, beyond what might be attributed to normal agi

There are no comments yet on this publication. Be the first to share your thoughts.


Seen <100 times

More articles like this

Kynurenines in chronic neurodegenerative disorders...

on Journal of neural transmission... November 2009

Novel therapeutic strategies for the treatment of...

on Diabetes/metabolism reviews September 1998

Novel therapeutic strategies.

on IDrugs : the investigational d... September 1999
More articles like this..